New York Xaljenz Thrombosis Lawyers
Xaljenz (Tofacitinib) Pulmonary Embolisms
Have you or a loved one experienced a blood clot, deep vein thrombosis
or pulmonary embolism while using Xaljenz sold by Pfizer? The drug was
approved by the FDA in 2012. Xaljenz is one of the new “JAK Inhibitors”
(janus kinase) used to treat moderate-to-severe active rheumatoid arthritis,
psoriatic arthritis and moderate-to-severe active ulcerative colitis.
A Rheumatology Data Safety Monitoring Board stated in February 2019 that
patients who received the 10 mg dose of Xaljenz were at a higher risk
of pulmonary embolism and death, compared with patients in this study
who were treated with a similar drug.
Our attorneys, Paul Rheingold and David Rheingold, have decades of litigation
experience involving pulmonary embolism injuries, particularly with hormonal
birth control, testosterone and inferior vena cava medical devices. Our
firm has represented thousands of clients and gained millions of dollars
in verdicts and settlements for other prescription drug cases.
Contact us to speak with a drug litigation partner from a
New York pharmaceutical litigation law firm.
Thrombois Warnings in Europe for Another JAK (Janis Kinase) Drug Sold to
Treat Rheumatoid Arthritis
A thrombosis is a potentially life-threatening blood clot that can start
in the leg and then travel to the lungs. The European Drug Agency required
the following warning on a similar Janus Kinase inhibitor drug which treats
“Thrombosis, including deep venous thrombosis (DVT) and pulmonary
embolism (PE), has been observed at an increased incidence in patients
treated compared to placebo. In addition, there were cases of arterial
thrombosis. Many of these adverse events were serious and some resulted
in death. Patients with symptoms of thrombosis should be promptly evaluated.”
Is an FDA Warning Coming for Rheumatoid Arthritis Drugs for Deep Vein Thrombosis
and Pulomanry Embolism Injuries and Deaths?
Independent medical groups have been publishing articles since 2017 based
on FDA adverse event data reporting (known as FAERS data) documenting
clot injuries in patients using this class of drug. One study suggested
the adverse event reports indicated that pulmonary thrombosis may be a
class-wide issue for JAK inhibitors. Researchers want future studies to
focus on dosage, other drugs being used, pre-existing conditions and larger
New York Firm Experienced in Dealing with Pharmaceutical Companies
Our firm has extensive litigation experience against Pfizer and other companies
marketing drugs associated with pulmonary embolisms. Our
New York defective drug attorneys handle a wide range of drug liability claims, including those involving
the prescription drug Xeljanz. Call (888) 260-0473 for a free case evaluation.
Please contact us today online or by telephone at
(888) 260-0473 to speak with an experienced New York drug liability law firm.